David Vicente

机构：Hospital Universitario Virgen Macarena · ORCID：0000-0002-6210-090X

发表论文 104 篇 · 总被引 18051 次 · h-index 33

代表论文

• Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study (2023 · Journal of Clinical Oncology · 被引 557)
• First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study (2023 · The Lancet · 被引 165)
• Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial (2024 · Nature Medicine · 被引 129)
• Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis (2021 · Nature Communications · 被引 63)
• Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC) (2021 · Clinical Lung Cancer · 被引 58)
• Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype (2023 · Nature Communications · 被引 26)